Discovery and Preclinical Domain
This domain encompasses most of the Institute’s laboratory-based cellular and molecular biology and preclinical research.
The scientists in the Discovery and Preclinical Domain aim to identify new avenues for the design of diagnostic, preventative and therapeutic strategies to tackle cardiovascular disease, diabetes and its complications. They aim to understand the cellular mechanisms of disease, biomarkers in the progression of disease and the pathways of gene expression.
A key focus of this domain is on translating exciting discoveries in the laboratory to clinical care.
This domain is led by researcher, Professor Andrew Murphy, Head of Haematopoiesis and Leukocyte Biology.